We are proud to spotlight a recent publication in Pharmaceutical Research, co-authored by Dr. John M. Newsam, former CEO of Tioga Research. This perspective article presents a rigorous overview of how predictive tools are transforming the development of topical drug products. It reflects many of the scientific principles that underpin Tioga’s own formulation and screening methodologies.
The authors propose an integrated framework that combines modeling, in vitro methods, and formulation science to better predict topical bioavailability, reduce reliance on animal testing, and streamline development timelines. This aligns with Tioga’s longstanding commitment to innovation in dermal drug delivery through approaches like our proprietary Cascade Screening™ platform.
Key contributions of the publication include:
Framework for Prediction:
Introduction of a conceptual model linking drug properties, formulation attributes, and skin biology to predict dermal absorption.
Integration of Tools:
Emphasis on combining in vitro permeation testing (IVPT), in vitro release testing (IVRT), and in silico modeling to reduce trial-and-error in formulation development.
Role of Formulation Design:
Discussion on how excipients and formulation architecture critically influence drug delivery through the skin barrier.
Regulatory Relevance:
Highlights the growing importance of predictive methods in regulatory science, especially with the global move toward alternatives to animal testing.
Call for Collaboration:
Encourages alignment between industry, academia, and regulators to advance the validation and adoption of predictive approaches.
This publication is a testament to the scientific rigor and thought leadership that Tioga brings to its partnerships in topical drug development.
Citation:
Godin B, Newsam JM, et al. Skin Delivery: Developing Predictive Tools to Optimize Topical Bioavailability. Pharm Res. 2024. PMID: 39299467
